These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2905703)

  • 1. High-performance liquid chromatographic determination of famotidine in urine.
    Rahman A; Hoffman NE
    J Chromatogr; 1988 Jul; 428(2):395-401. PubMed ID: 2905703
    [No Abstract]   [Full Text] [Related]  

  • 2. Analytical method for the quantification of famotidine, an H2-receptor blocker, in plasma and urine.
    Vincek WC; Constanzer ML; Hessey GA; Bayne WF
    J Chromatogr; 1985 Mar; 338(2):438-43. PubMed ID: 2860117
    [No Abstract]   [Full Text] [Related]  

  • 3. HPLC reveals famotidine in the urine up to five days after a single 20 mg oral dose.
    Bologna M; Napolitano T; Biordi L; Carlucci G
    Drugs Exp Clin Res; 1988; 14(6):419-21. PubMed ID: 2905638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of famotidine in man.
    Kroemer H; Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: application to the analysis of ranitidine and its metabolites in human volunteers.
    Ashiru DA; Patel R; Basit AW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Dec; 860(2):235-40. PubMed ID: 18006395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of plasma, urine and gastric juice concentrations of famotidine using high performance liquid chromatography.
    Bologna M; Biordi L; Napolitano T; Carlucci G
    Int J Clin Pharmacol Res; 1988; 8(5):335-40. PubMed ID: 3229873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Liquid chromatography in pharmaceutical analysis: determination in tablets of famotidine, a new H2-antagonists].
    Ficarra R; Ficarra P; Calabrò ML
    Farmaco Prat; 1987 Nov; 42(11):307-12. PubMed ID: 2893743
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolites of ebrotidine, a new H2-receptor antagonist, in human urine.
    Rozman E; Galcerán MT; Anglada L; Albet C
    J Pharm Sci; 1994 Feb; 83(2):252-4. PubMed ID: 7909553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of ebrotidine. A review.
    Rozman E; Albet C; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):486-9. PubMed ID: 9205749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
    Lin JH; Chremos AN; Yeh KC; Antonello J; Hessey GA
    Eur J Clin Pharmacol; 1988; 34(1):41-6. PubMed ID: 2896129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the metabolism of ebrotidine in human urine by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.
    Rozman E; Galceran MT; Anglada L; Albet C
    Drug Metab Dispos; 1995 Sep; 23(9):976-81. PubMed ID: 8565788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of famotidine in low-volume human plasma by normal-phase liquid chromatography/tandem mass spectrometry.
    Zhong L; Eisenhandler R; Yeh KC
    J Mass Spectrom; 2001 Jul; 36(7):736-41. PubMed ID: 11473396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-performance liquid chromatographic assay for nizatidine, a new H2 blocker, in human plasma and urine using disposable solid-phase extraction columns.
    Carlucci G
    J Chromatogr; 1990 Feb; 525(2):490-4. PubMed ID: 1970345
    [No Abstract]   [Full Text] [Related]  

  • 14. Spectrofluorimetric analysis of famotidine in pharmaceutical preparations and biological fluids by derivatization with benzoin.
    Alamgir M; Khuhawar MY; Memon SQ; Hayat A; Zounr RA
    Spectrochim Acta A Mol Biomol Spectrosc; 2015 Jan; 134():449-52. PubMed ID: 25033237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of nizatidine and two of its main metabolites in human serum using high-performance liquid chromatography.
    Tracqui A; Kintz P; Mangin P
    J Chromatogr; 1990 Aug; 529(2):369-76. PubMed ID: 1977754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of metformin, cimetidine, famotidine, and ranitidine in human serum and dosage formulations using HPLC with UV detection.
    Arayne MS; Sultana N; Zuberi MH; Siddiqui FA
    J Chromatogr Sci; 2010 Oct; 48(9):721-5. PubMed ID: 20875233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High pressure liquid-liquid chromatography. Quantitative determination of histamine H2 antagonists].
    Gaetani E; Laureri CF; Ronchini F
    Farmaco Prat; 1978 Nov; 33(11):484-8. PubMed ID: 35364
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of a new H2 receptor antagonist, 3-amino-5-[3-[4-(1-piperidinoindanyloxy)]propylamino]-1-methyl-1 H-1,2,4-triazole, in human plasma and urine by high-performance liquid chromatography.
    Miksic JR; Rivel ER; Rush K
    J Chromatogr; 1988 Jun; 428(1):113-21. PubMed ID: 2902101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-performance liquid chromatographic determination of a new H2 blocker (ORF 17 910) in plasma.
    Huang SM; Tran-Phan H
    J Chromatogr; 1987 Dec; 423():358-64. PubMed ID: 2895116
    [No Abstract]   [Full Text] [Related]  

  • 20. The antisecretory profile of action of the H2-receptor antagonists, famotidine, loxtidine, ranitidine and L-643,441 on the rat isolated gastric mucosa.
    Reeves JJ; Stables R
    Agents Actions; 1987 Feb; 20(1-2):22-8. PubMed ID: 2883848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.